A new drug to help treat type 2 diabetes has been shown to improve blood sugar levels and enable weight loss in a Germany study.MEDI0382, developed by MedImmune, is a balanced glucagon-like peptide-1 (GLP-1) and glucagon receptor dual agonist. It is administered subcutaneously, and researchers believe that following this trial the drug has potential as an obesity and type 2 diabetes therapy.
The trial involved 51 overweight people with type 2 diabetes aged 18-65, 25 of whom were randomly assigned to MEDI0382 and 26 to placebo.
Those who took the drug had significantly lower fasting blood sugar levels as well as lower levels after meals. HbA1c levels also decreased among the MEDI0382 group, who also lost more weight and had lower blood pressure compared with the placebo group. Moreover, there was no increase in hypoglycemia among the MEDI0382 group.